INFORMATIONAL PURPOSES ONLY. Not medical, legal, or travel advice. Verify with official sources before acting. See corrections log.
State-by-state comparison: have cell therapy statute references. Interactive map and sortable table for all 50 US states.
| State | Value | Verified | Source |
|---|---|---|---|
| Alaska | No explicit state statute identified. | 2026-10-09 | Source |
| Alabama | No explicit state statute identified. | 2026-10-09 | Source |
| Arkansas | No explicit state statute identified. | 2026-10-09 | Source |
| Arizona | No explicit state statute identified. | 2026-10-09 | Source |
| California | Cal. Bus. & Prof. Code § 684 | 2026-10-09 | Source |
| Colorado | No explicit state statute identified. | 2026-10-09 | Source |
| Connecticut | No explicit state statute identified. | 2026-10-09 | Source |
| District of Columbia | No explicit state statute identified. | 2026-10-09 | Source |
| Delaware | No explicit state statute identified. | 2026-10-09 | Source |
| Florida | Fla. Stat. §§ 458.3245, 459.0127 (SB 1768, 2025); § 461.011 (CS/CS/SB 1092, ch. 2026-124) | 2026-10-09 | Source |
| Georgia | O.C.G.A. § 43-34-49 (HB 1275, 2026) | 2026-10-09 | Source |
| Hawaii | No explicit state statute identified. | 2026-10-09 | Source |
| Iowa | No explicit state statute identified. | 2026-10-09 | Source |
| Idaho | No explicit state statute identified. | 2026-10-09 | Source |
| Illinois | No explicit state statute identified. | 2026-10-09 | Source |
| Indiana | No explicit state statute identified. | 2026-10-09 | Source |
| Kansas | No explicit state statute identified. | 2026-10-09 | Source |
| Kentucky | No explicit state statute identified. | 2026-10-09 | Source |
| Louisiana | No stem-cell-specific statute identified; La. R.S. 40:1300.71-1300.79 (Hope for Louisiana Patients Law, Acts 2024, No. 750) covers individualized investigational treatments, including perinatal-derived products. | 2026-10-09 | Source |
| Massachusetts | No explicit state statute identified. | 2026-10-09 | Source |
| Maryland | No explicit state statute identified. | 2026-10-09 | Source |
| Maine | No explicit state statute identified. | 2026-10-09 | Source |
| Michigan | No explicit state statute identified. | 2026-10-09 | Source |
| Minnesota | No explicit state statute identified. | 2026-10-09 | Source |
| Missouri | No explicit state statute identified. | 2026-10-09 | Source |
| Mississippi | Miss. Code Ann. § 41-131-1 (Right-to-Try Act, as amended by SB 2830, 2020) | 2026-10-09 | Source |
| Montana | No stem-cell-specific statute; general Right to Try Act, Mont. Code Ann. §§ 50-12-101 to 50-12-110 (amended by Ch. 621, L. 2025). | 2026-10-09 | Source |
| North Carolina | N.C. Gen. Stat. § 90-325.1 et seq. (Right to Try Act, as amended by H.B. 934, 2019) | 2026-10-09 | Source |
| North Dakota | No explicit state statute identified. | 2026-10-09 | Source |
| Nebraska | Neb. Rev. Stat. § 38-1,147 (LB 752, 2022) | 2026-10-09 | Source |
| New Hampshire | No explicit state statute identified. | 2026-10-09 | Source |
| New Jersey | No explicit state statute identified. | 2026-10-09 | Source |
| New Mexico | No explicit state statute identified. | 2026-10-09 | Source |
| Nevada | No stem-cell-specific statute identified; Nevada's 2023 individualized investigational treatment law is general (not stem-cell-specific). | 2026-10-09 | Source |
| New York | No explicit state statute identified. | 2026-10-09 | Source |
| Ohio | No explicit state statute identified. | 2026-10-09 | Source |
| Oklahoma | No explicit state statute identified. | 2026-10-09 | Source |
| Oregon | No explicit state statute identified. | 2026-10-09 | Source |
| Pennsylvania | No explicit state statute identified. | 2026-10-09 | Source |
| Rhode Island | No explicit state statute identified. | 2026-10-09 | Source |
| South Carolina | No explicit state statute identified. | 2026-10-09 | Source |
| South Dakota | No explicit state statute identified. | 2026-10-09 | Source |
| Tennessee | 2026 Tenn. Pub. Acts ch. 1016 (HB 2246), new section in Tenn. Code Ann. Title 63, Chapter 6, Part 2; effective July 1, 2026 | 2026-10-09 | Source |
| Texas | Tex. Health & Safety Code §§ 1003.051-1003.060 (HB 810, 2017; amended HB 3148, 2019) | 2026-10-09 | Source |
| Utah | Utah Code § 58-1-512 (enacted 2024 by S.B. 199, Laws of Utah 2024 ch. 265; amended by S.B. 55, effective May 6, 2026) | 2026-10-09 | Source |
| Virginia | No explicit state statute identified. | 2026-10-09 | Source |
| Vermont | 18 V.S.A. §§ 4501-4502 (chapter 87, Stem Cell Products; Act 61 of 2021, S.22) | 2026-10-09 | Source |
| Washington | 2026-10-09 | Source | |
| Wisconsin | No explicit state statute identified. | 2026-10-09 | Source |
| West Virginia | No explicit state statute identified. | 2026-10-09 | Source |
| Wyoming | Wyo. Stat. §§ 35-4-1101 to 35-4-1106 (Stem Cell Freedom Act; SF0048, 2026 Wyo. Sess. Laws ch. 64, effective July 1, 2026) | 2026-10-09 | Source |
Add an interactive map to your site. Always stays current.